GlassScriptPhysician profile
Kory Stephen Drake
NPI 1114423522
$906.26
in general payments reported to CMS, 2019-2025
13 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2023: $99.80 · 2024: $366 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $234.26 | 2023-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $156.23 | 2020-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $113.43 | 2024-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $82.00 | 2024-2025 | |
| Novo Nordisk INC | $66.23 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ani Pharmaceuticals, INC. | $55.30 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $50.77 | 2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $36.92 | 2024 | Acthar |
| Nxstage Medical, INC. | $33.20 | 2023 | Nxstage Cartridge Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.01 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $21.83 | 2023 | Krystexxa |
| Ardelyx, INC. | $16.10 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $15.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kory Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.